Barriers to Penicillin allergy management in India and Sri Lanka, and bespoke mitigation strategies.

Syphilis is a re-emerging disease, and suspicion of syphilis infection should be considered in all cases with atypical skin manifestations, mainly whe...

T. Vivoda et al.

Psoriasis skin lesions are generally thought to occur before psoriatic arthritis (PsA) develops. However, PsA may be challenging to diagnose in the ab...

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disorder frequently associated with immune-mediated comorbidities, including inflammatory...

From 2019 to 2023, 7133 Italian consecutive patients underwent patch test with 2-HEMA. 147 (2.1%) resulted positive (78.2% relevant), with an increasi...

The role biologics play in skin cancer among patients with inflammatory disease (ID) is uncertain. Skin cancer risk in patients with ID is elevated regardless of therapy, and there is a paucity of longitudinal data evaluating biologics that accounts for these ID-related confounders.

AbstractObjectiveCommon adverse events associated with apalutamide include skin rashes and occur more frequently in Japanese patients. This study used relative dose intensity (RDI) and body surface area (BSA) to investigate the risk of skin adverse events and the efficacy of apalutamide in patients with prostate cancer.MethodsWe retrospectively reviewed data from 63 patients with prostate cancer who were treated with an initial dose of 240 mg apalutamide, and RDI (%) was calculated. Patient backgrounds were compared, and factors contributing to rash development were analyzed. Progression-free survival (PFS), defined as the time to castration-resistant prostate cancer, was analyzed using overall RDI/BSA in metastatic castration-sensitive prostate cancer (mCSPC) patients.ResultsThe receiver operating characteristic curve analysis showed that RDI/BSA had a slightly stronger association with rash occurrence than RDI/kg. Univariate analysis identified age and RDI/BSA as significant risk factors for rash occurrence, particularly when both an age cutoff of 72 years and a RDI/BSA cutoff of 56 were met. PFS in mCSPC patients showed no significant differences among tRDI/BSA groups (<36, 36–55, >55) or between patients with and without dose reductions. Cutoff points (36 and 55) were based on the maximum tRDI/BSA values assuming continuous administration of 120 mg or 180 mg apalutamide in patients with a minimum BSA of 1.36 m2.ConclusionsAge and RDI/BSA were associated with rash occurrence, suggesting a need for dose reduction of apalutamide. A dose reduction to 180 or 120 mg may be appropriate in such cases when considering efficacy.